Esperion Therapeutics Inc at Needham Healthcare Conference (Virtual) Transcript
Hi. Good morning. Welcome to Needham's 22nd annual healthcare conference. I'm Serge Belanger, one of the senior healthcare analysts at Needham. And for our next session, we're happy to have the Esperion Therapeutics team. We have the CEO, Sheldon Koenig; as well as the CFO, Ben Halladay.
So I'll hand it over to Sheldon. And you can tell us a little bit about some of the important data that the company recently reported just over a month ago at the ACC meeting and how it shapes the franchise of the bempedoic acid and the future of the company.
Great. Thank you, Serge. First of all, on behalf of Esperion and all the employees, I just want to thank you and Needham for having us here at today's conference. We're always excited. You said, what's next? You're going to hear me say what's next quite a lot, obviously, based upon the names of NEXLETOL and NEXLIZET.
As you mentioned, on March 4, Dr. Steve Nissen presented our ACC CLEAR
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
